Loading…
Loading…
Gold's recent correction has created an attractive entry point for investors, even as short-term headwinds continue to pressure prices, according to one portfolio manager.
For most of the last four decades, the 60/40 portfolio did exactly what it promised. Stocks climbed, bonds offset the losses when they didn't, and advisors could build client portfolios around a reliably predictable balance.
Managed futures funds spent most of the past decade as a footnote in portfolio construction conversations.
The S&P 500 has shed roughly its worst drawdown in the past 12 months during the early months of 2026, as tariff escalation and macro uncertainty rattled equity markets.
The KraneShares Mount Lucas Managed Futures Index Strategy ETF offers strong diversification benefits via algorithmic trend-following across commodities, currencies, and global bonds. I see heightened stagflation risks for 2026, making KMLM and managed futures allocations especially timely for portfolios exposed to equities and bonds. Allocating 20% to managed futures like KMLM in a 50-30-20 portfolio historically improved returns, reduced volatility, and softened drawdowns versus traditional 60/40 mixes.
The KraneShares Mount Lucas Managed Futures Index Strategy ETF (NYSEARCA:KMLM) offers a 5% dividend yield based on its most recent annual distribution.
Abbington Investment Group purchased a new position in shares of KraneShares Mount Lucas Managed Futures Index Strategy ETF (NYSEARCA:KMLM) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 150,884 shares of the company's stock, valued at approximately $4,063,000. KraneShares Mount
Managed future ETFs are funds that attempt to produce positive expected returns and some diversification to equities and fixed income. KraneShares Mount Lucas Managed Futures Index Strategy ETF offers low correlations with the S&P 500 and long-term US government bonds, which is great for diversification. KMLM has performed poorly relative to a couple of its key peers since 2022, making it an underappreciated fund, in my view.